Protocol Ledger

NCT07409181 · Phase II · RECRUITING

A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)

Interventional Phase II clinical trial protocol NCT07409181 sponsored by Boehringer Ingelheim in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-04-20 Enrollment: 405 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07409181
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)405 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07409181
Protocol FieldVerified Registry Value
NCT IdentifierNCT07409181
Consolidated Lead SponsorBoehringer Ingelheim
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment405 participants (ESTIMATED)
Registered Start Date2026-04-20
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07409181
Hospital Research SiteLocationSite Profile
UC San Diego Health and Moores Cancer CenterSan Diego, CAOpen Hospital Dossier ->
UCLA Health and Jonsson Comprehensive Cancer CenterLos Angeles, CAOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Boehringer Ingelheim across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI